# Profiling cancer-related gene mutations in oral squamous cell carcinoma from Japanese patients by targeted amplicon sequencing

# SUPPLEMENTARY MATERIALS

			1	1							
ABL1	BTK	DDR2	FLT1	ITGA9	MLH1	PAK3	RALGDS	ICF12			
ABL2	BUB1B	DEK	FLT3	ITGB2	MLL	PAX5	RARA	TCF3			
ACVR2A	CARD11	DICER1	FLT4	ITGB3	MLL2	PAX7	RB1	TOF7L1			
ADAMTS20	CASC5	DNMT3A	FN1	JAK1	MLL3	PALB2	RECQL4	TCF7L2			
AFF1	CBL	DPYD	FOXL2	JAK2	MLLT10	PARP1	REL	TCL1A			
AFF3	CCND1	DST	FOXO1	JAK3	MMP2	PAX3	RET	TET1			
AKAP9	CCND2	EGFR	FOXO3	JUN	MN1	PAX8	RHOH	TET2			
AKT1	CCNE1	EML4	FOXP1	KAT6A	MPL	PBRM1	RNASEL	TFE3			
AKT2	CD79A	EP300	FOXP4	KAT6B	MRE11A	PBX1	RNF2	TGFBR2			
AKT3	CD79B	EP400	FZR1	KDM5C	MSH2	PDE4DIP	RNF213	TGM7			
ALK	CDC73	EPHA3	G6PD	KDM6A	MSH6	PDGFB	ROS1	THBS1			
APC	CDH1	EPHA7	GATA1	KDR	MTOR	PDGFRA	RPS6KA2	TIMP3			
AR	CDH11	EPHB1	GATA2	KEAP1	MTR	PDGFRB	RRM1	TLR4			
ARID1A	CDH2	EPHB4	GATA3	KIT	MTRR	PER1	RUNX1	TLX1			
ARID2	CDH20	EPHB6	GDNF	KLF6	MUC1	PGAP3	RUNX1T1	TNFAIP3			
ARNT	CDH5	ERBB2	GNA11	KRAS	MUTYH	PHOX2B	SAMD9	TNFRSF14			
ASXL1	CDK12	ERBB3	GNAQ	LAMP1	МҮВ	PIK3C2B	SBDS	TNK2			
ATF1	CDK4	ERBB4	GNAS	LCK	MYC	РІКЗСА	SDHA	TOP1			
ATM	CDK6	ERCC1	GPR124	LIFR	MYCL1	РІКЗСВ	SDHB	TP53			
ATR	CDK8	ERCC2	GRM8	LPHN3	MYCN	PIK3CD	SDHC	TPR			
ATRX	CDKN2A	ERCC3	GUCY1A2	POT1	MYD88	PIK3CG	SDHD	TRIM24			
AURKA	CDKN2B	ERCC4	HCAR1	LPP	MYH11	PIK3R1	SEPT9	TRIM33			
AURKB	CDKN2C	ERCC5	HIF1A	LRP1B	МҮН9	PIK3R2	SETD2	TRIP11			
AURKC	CEBPA	ERG	HLF	LTF	NBN	PIM1	SF3B1	TRRAP			
AXL	CHEK1	ESR1	HNF1A	LTK	NCOA1	PKHD1	SGK1	TSC1			
BAI3	CHEK2	ETS1	ноокз	MAF	NCOA2	PLAG1	SH2D1A	TSC2			
BAP1	CIC	ETV1	HRAS	MAFB	NCOA4	PLCG1	SMAD2	TSHR			
BCL10	CKS1B	ETV4	HSP90AA1	MAGEA1	NF1	PLEKHG5	SMAD4	UBR5			
BCL11A	CMPK1	EXT1	HSP90AB1	MAGI1	NF2	PML	SMARCA4	UGT1A1			
BCL11B	COL1A1	EXT2	ICK	MALT1	NFE2L2	PMS1	SMARCB1	USP9X			
BCL2	CRBN	EZH2	IDH1	MAML2	NFKB1	PMS2	SMO	VHL			
BCL2L1	CREB1	FAM123B	IDH2	MAP2K1	NFKB2	POU5F1	SMUG1	WAS			
BCL2L2	CREBBP	FANCA	IGF1R	MAP2K2	NIN	PPARG	SOCS1	WHSC1			
BCL3	CRKL	FANCC	IGF2	MAP2K4	NKX2-1	PPP2R1A	SOX11	WRN			
BCL6	CRTC1	FANCD2	IGF2R	MAP3K7	NLRP1	PRDM1	SOX2	WT1			
BCL9	CSF1R	FANCF	IKBKB	MAPK1	<i>NOTCH1</i>	PRKAR1A	SRC	XPA			
BCR	CSMD3	FANCG	IKBKE	MAPK8	<i>NOTCH2</i>	PRKDC	SSX1	XPC			
BIRC2	CTNNA1	FAS	IKZF1	MARK1	<i>NOTCH4</i>	PSIP1	STK11	XPO1			
BIRC3	CTNNB1	FBXW7	IL2	MARK4	NPM1	PTCH1	STK36	XRCC2			
BIRC5	CYLD	FGFR1	IL21R	MBD1	NRAS	PTEN	SUFU	ZNF384			
BLM	CYP2C19	FGFR2	IL6ST	MCL1	NSD1	PTGS2	SYK	ZNF521			
BLNK	CYP2D6	FGFR3	IL7R	MDM2	NTRK1	PTPN11	SYNE1				
BMPR1A	DAXX	FGFR4	ING4	MDM4	NTRK3	PTPRD	TAF1				
BRAF	DCC	FH	IRF4	MEN1	NUMA1	PTPRT	TAF1L				
BRD3	DDB2	FLCN	IRS2	MET	NUP214	RAD50	TAL1				
BRIP1		FLI1	ITGA10	MITE	NUP98	RAF1	TBX22				
		1	1		1.10, 00	1		1			

Supplementary Figure 1: Ion Ampliseq Comprehensive Cancer Panel gene list.



**Supplementary Figure 2: Mutation spectrum of single nucleotide substitutions. (A)** The major nucleotide change was a C/G>T/A transition in this study. The second most frequent mutation was a C/G>A/T transversion. **(B)** Spectrum of single nucleotide substitutions in the exome-sequencing studies of head and neck (HNSCC), esophageal (ESCC), and lung squamous cell carcinoma (LSCC) [1] (Song Y et al. Nature 2014; 509:91-95).

# SUPPLEMENTARY REFERENCE

 Song Y, Li L, Ou Y, Gao Z, Li E, Li X, Zhang W, Wang J, Xu L, Zhou Y, Ma X, Liu L, Zhao Z, et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 2014; 509:91-5.

# **Oncotarget, Supplementary Materials 2017**



(Continued)



**Supplementary Figure 3: Verification of identified mutations by Sanger sequencing.** Sanger sequencing traces for 30 variants (19 SNVs and 11 InDels) are shown. The position of the called variant is indicated by an arrow. The variant effect, cDNA position, and variant frequency are also given.

Α



В



**Supplementary Figure 4: Examples of SNVs and InDels detected by NGS.** Two types of nonsynonymous mutations from OSCC patients as shown by the IGV. (A) A missense mutation detected in exon 8 of the *TP53*gene (p.Arg273Cys, c.817C>T) in patient No. 6. (B) A 1-bp deletion detected in exon 2 of the *CDKN2A* gene (c.155\_155delT) in patient No. 14.





**Supplementary Figure 5: Mutation distribution in the function domains of** *TP53* **in OSCC tumors.** Any position with a mutation contains a circle (green, missense mutation; black, nonsense mutation; yellow, in-frame deletion; orange, frameshift deletion; and blue, splice site mutation), and the length of the line depends on the number of mutations detected at that codon. The colored boxes are specific functional domains. Above the lollipops, the frequent variants are annotated as the amino-acid change at that specific site.

Patient No.23		Patient No.4
HUMAN         305 A         C           MACMU         305 A         C           MOUSE         305 A         C           CHICK         308 A         C           ANOCA         310 A         C           XENLA         304 A         C           DANRE         304 A         C           BILA         945 N         Y	Q N G G T C H N T 315 Q N G G T C H N T 315 Q N G G T C H N T 315 Q N G G T C H N T 315 Q N G G T C H N T 315 Q N G G T C H N T 319 Q N G G T C H N T 314 Q N G G T C H N T 314 P D N S E C S W K 955	347 G A T C H D R V A S F 357 347 G A T C H D R V A 355 347 G A T C H D R V A 355 350 G A T C H D R V A 358 351 G A T C H D R V A 358 351 G A T C H D R V A S F 361 346 G A T C H D R V A 354 346 G A T C H D R V A 354 346 G A T C H D R V A 354
	Gly310Arg	Asp352Gly
Patient No.37           HUMAN         360         E         C           MACMU         361         -         C           MOUSE         361         -         C           CHICK         364         -         C           ANOCA         364         E         C           XENLA         360         -         C           DANRE         360         -         C           BILA         1029         S         S	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Patient No.9 1009 C P P G F T G S Y C Q 1019 1009 C P P G F T G S Y C Q 1019 1009 C P P G F T G S Y C Q 1019 1012 C P S G F T G S Y C E 1022 1013 C P P G F T G I Y C E 1023 1008 C P P G F T G I Y C Q 1017 1006 D A G 1909 ▲
	Arg365Cys	Thr1014Met
Patient No.12           HUMAN         1180         C         S           MACMU         1180         C         S           MOUSE         1180         C         S           CHICK         1180         C         S           CHICK         1183         C         S           ANOCA         1184         C         S           XENLA         1179         C         S           DANRE         1178         C         S           BILA         2152         C         E	E E I D E C L S H 1190 E E I D E C L S H 1190 E E I N E C L S Q 1190 E E I N E C L S H 1193 E E I N E C L S H 1193 E E I N E C L S H 1194 E E I N E C L S H 1189 K E I N E C L S Q 1188 I - D D W C N E F 2161	Patient No.27 1378 F T G P E C Q F P A S 1388 1378 F T G P E C Q F P A S 1388 1378 F T G P E C Q F P A S 1388 1378 F T G P E C Q F P A S 1388 1381 F T G P E C Q Y P A S 1391 1382 F T G P E C E F P S S 1392 1377 Y T G A T C Q Y P V I 1387 1376 F S G H E C Q T R M D 1386 2513 F Y G R Y - M T V D P 2522
	Asp1185Asn	Cys1383Tyr
Patient No.8           Patient No.19           HUMAN         1400         Q         G           MACMU         1400         Q         G           MOUSE         1400         Q         G           MOUSE         1400         Q         G           ANOCA         1402         G         G           XENLA         1398         G         G           DANRE         1397         G         G           BILA         2533         N         G	T C E P T S E 1408 T C E F L S D - A 1411 T C Q F A K E P P 1413 T C Q F F A E 1406 T C Q P I S D 1405 N C S I D D D D D 2543	Patient No.22 1952 A D A N I Q D N M G R 1962 1952 A D A N I Q D N M G R 1962 1942 A D A N I Q D N M G R 1952 1955 A D A N I Q D N M G R 1965 1958 A D A N I Q D H M G K 1968 1949 A D A N I Q D N M G R 1959 1939 A D A N I Q D N M G R 1949 3154 T Q T Y H F E Q F G E 3164
	Pro1405His	GIn1957Pro
Patient No.33           HUMAN         2074         Y         E           MACMU         2074         Y         E           MOUSE         2064         Y         E           CHICK         2077         Y         E           ANOCA         1987         -         -           XENLA         2071         Y         E           DANRE         2062         Y         E           BILA         3373         T         E	T A K V L L D H F 2084 T A K V L L D H F 2084 T A K V L L D H F 2084 T A K V L L D H F 2074 T A K V L L D H F 2087 1987 T A K V L L D H F 2081 T A K V L L D H F 2081 T A K V L L D H F 2072 I G K Y 3378	
	Val2079Leu	

**Supplementary Figure 6: Detected** *NOTCH1* **mutation sites are well conserved between species.** Sequence homology of Notch1 mutation sites from different species is shown. HUMAN, *Homo sapiens*; MACMU, monkey; MOUSE, mouse; CHICK, chicken; ANOCA, lizard; XENLA, frog; DANRE, zebrafish; and BILA, *Trichinella*.



**Supplementary Figure 7: Detected** *NOTCH1* **mutation sites are well conserved throughout the Notch family.** Sequence homology of *NOTCH1* mutation sites with three human paralogs (*NOTCH2*, *NOTCH3*, and *NOTCH4*). The alignment was generated using the UniProt workflow.

#### chr1 chr2 chr3 chr4 chr5 chr6 chr7 chr8 chr9 chr10 p16.1 p15.2 p15.1 p14 q12 q13.1 q13.3 q22.1 q24 q26 p21.3 014 p23.1 p22 p24. p22.3 p21.3 p14.3 p14.1 q11.2 q11.2 q21.1 q22.1 q31.1 p12 p34. g12.1 GFR **p32**.3 p11 . p16.1 q21. p14.1 p12.3 à . o21 p31.1 p12 p11.2 q11.2 q14.3 q15 q23. ж q21.3 q22.1 q16.1 q21 q22.3 q25.3 q25.3 q25.1 q23.1 q23.2 q31.1 q23.3 8 q14. q12 . q28.3 q31.2 224.8 g22.1 a32 q34 8 q24 q26.1 q24.3 q31.1 q32.1 q32.3 q33.1 q34 q35 q32.1 q32.3 q34.3 q25.3 🛢 q32. q41 q43, 🗖 37.8 chr15 chr16 chr19 chr11 chr12 chr13 chr14 chr17 chr18 chr20 p13.3 p13.2 p12.1 p15.4 p15.1 p13 p12 p11.2 011.7 q1112 q12 q21.1 011. 012 011.2 q11.2 q12.3 q12.3 q21.2 e11.j 011.2 012 q14 ERBB2 q1 q12.1 q22 17q12 q21. q21 925.8 q14.1 q22.3 ATM q31.1 q21. AKT1 q23.1 32 14a32. q23.3 11q22-q23 chr21 chr22 chrY chrX 211 p11.2 p22.2 p21.1 q21.1 q21.3 q23 q25 q28 q12. Patient No.43

**Supplementary Figure 8: Example of an OSCC case with CNVs.** Visualization of CNVs over the entire genome in the karyotype view. The decreased and increased copy numbers are indicated in blue and red, respectively.

# www.impactjournals.com/oncotarget/

# **Oncotarget, Supplementary Materials 2017**

		S CITED OF THE STATE S									3 THE BOOTER BREED													S CHINGHINE I POINT					
			2 October		1 CONTRACT								S OCCUPIED			a compo							Summe 2	a contraction				300	3 Da
			Patient No.1					dillio f	S CHIERDORNER S	1000	I	Patient No.6					a oans	872 O(11)		i Callan	Patient No.12								
												S OTHER THE DESIGN OF THE PARTY			S (BEIDER BARRED S		E CERTIFICATION E							S CHINALINA CONTRACTOR S			STREET STREET		
			S OCTION											2 October										S OCHENIT					
	3 OM	5 0(1 C	Patient No.15							0000	o		5 (M) 3	Patient No.19					000		1000	Patient No.21							
													STREET PROPERTY STREET		SULUE BUNCT		S CENTRAL STREET		S CIDARTINIAN)										
						I DITTO								a comercito			THE STREET				4 CHEVREN P			T OLIVIAN IS		THE PARTY I			
2 OMID	2 OCTID	1 011 -		Pat	ient	No.	.22				a och		3 Caller		Pati	ent	No.2	23		3 0 <b>01</b> 19	- Comp				Pa	tien	t No	.26	
				S CHINESE WARDEN S							S AN IN STATE OF THE OWNER	S THEFT DUTING STATES									STREET BUILD STREET					CITIERINE CONTRACTOR S			
		1 COLUMN											100										1 COLUMN	a Demand				3	
	a22 00111	3 00111	Patient No.33							ea Oralli	3 OCIII)		100		Patient No.37					9. H Patient N							No.	44	

**Supplementary Figure 9: Examples of OSCC cases with CNVs.** Visualization of CNVs over the entire genome in the karyotype view. The decreased and increased copy numbers are indicated in blue and red, respectively.



Supplementary Figure 10: qPCR copy number analysis. Relative DNA copy number was confirmed by quantitative real-time PCR using a KOD SYBR qPCR mix (Toyobo, Osaka, Japan) and the 7900HT real-time PCR system (Applied Biosystems). DNA content per haploid genome was normalized to that of a repetitive element, Line-1, and calculated by the comparative CT relative quantification method. DNA copy number relative to normal diploid leukocyte DNA was shown in Y axis. All assays were performed in triplicate. Copy number gains were considered when copy number was higher than 3.0 each gene. NGS results are presented at the bottom of the graph. The sequences of the primers used were as follows: CCND1, 5'-AATAAAAATTGCGGGTATTTTCTG-3' (sense) and 5'-TCCCACGAAACGCTACTTCT-3' CCND2, 5'-CTGTTTCTGAGTCTCTGCAGTCT-3' and 5'-CCCACACTTCCAGTTGCGAT-3' (antisense); (sense) (antisense); HRAS 5'- CCTCAGCCGAAAACCAAGATC-3' (sense) and 5'- CTTGAACATCCCAAATGCCAC-3' (antisense); NRAS, 5'- TTCTGGCATCAGTGAAACGC-3' (sense) and 5'- ATCTGTCCAAAGCAGGGGAG-3' (antisense); KRAS, 5'-AGAGCTGGCACAGAGACCAAAC-3' (sense) and 5'- AGGCCTTTGGTATACGACCCA-3' (antisense); Line-1 as internal control, 5'-AAAGCCGCTCAACTACATGG-3' (sense) and 5'- TGCTTTGAATGCGTCCCAGAG-3' (antisense).



**Supplementary Figure 11: Expression of endogenous** *CCND1* and *CCND2* in a panel of cell lines. mRNA expression of *CCND1* (A) and *CCND2* (B) in OSCC cell lines was measured by real time RT-PCR using TaqMan Gene Expression assays and a 7900HT real-time PCR system (Applied Biosystems) according to the manufacturer's protocol. CNV results from NGS are presented at the top of the graph. The primer/probe sets used were as follows: *CCND1*, Hs00765553\_m1; *CCND2*, Hs00153380\_m1; and GAPDH, Hs99999905\_m1. The data were normalized to the expression of the housekeeping gene *GAPDH* (% of GAPDH).

# **Oncotarget, Supplementary Materials 2017**



**Supplementary Figure 12: Kaplan–Meier curves of overall OSCC patient survival.** Kaplan–Meier estimates of overall survival among patients according to *TP53* mutation (A), *NOTCH1* mutation (B), *CDKN2A* mutation (C), *PIK3CA* mutation (D), RTK-RAS pathway alteration (E) and stage (F) (*P*, log-rank test). Analyses were carried out using Prism 6 (GraphPad Software, San Diego, CA, USA).

### Supplementary Table 1: Summary of targeted amplicon sequencing data for OSCC

See Supplementary File 1

# Supplementary Table 2: Full description of targeted amplicon sequencing data for OSCC tissues

See Supplementary File 2

#### Supplementary Table 3: Validated mutations by Sanger sequencing

See Supplementary File 3

#### Supplementary Table 4: Somatic nonsynonymous mutations found in OSCC cell lines

See Supplementary File 4

# Supplementary Table 5: Somatic nonsynonymous mutations found in 47 OSCC

See Supplementary File 5

### Supplementary Table 6: NOTCH1 mutations detected in this study

See Supplementary File 6

#### Supplementary Table 7: List of somatic mutations in CDKN2A and PIK3CA genes

See Supplementary File 7